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Abstract
Objectives Oral fields of visually normal and non-
dysplastic mucosa (ODFs) may represent the precursors of
oral potentially malignant lesions (OPMLs). Aim of the
study was to provide new evidence for the concept of the
“field carcinogenesis” model by comparing the ODF and
OPML genomic aberration profiles obtained by high
resolution DNA flow cytometry (hr DNA-FCM) and
array-Comparative Genomic Hybridization (a-CGH). A
second aim was to investigate if specific CGH aberrations
were associated with DNA aneuploidy.
Methods Nineteen patients with single OPMLs were
recruited for the study. In parallel with obtaining samples
of OPML tissue from 11 leukoplakias without dysplasia
(nd-OPMLs) and 8 with dysplasia (d-OPMLs), we also
obtained samples from distant ODFs. DNA aneuploid
nuclei detected by hr DNA-FCM were physically separated,
based on DNA content, from the DNA diploid components
with a DNA-FCM-Sorter. These relatively pure subpopula-
tions of epithelial nuclei were then submitted to DNA
extraction and a-CGH for a genome-wide analysis of DNA
copy number aberrations (CNAs).
Results The frequencies of DNA aneuploidy (DI≠1) among
ODFs and OPMLs were respectively 5.3% and 32%. The
DI aneuploid values of ODFs and nd-OPMLs were all near-
diploid (DI≠1 and DI≤1.4), while for d-OPMLs were high-
aneuploid (DI>1.4) in 40% of the cases. CNA averages
were 1.9 in ODFs and 6.5 in OPMLs. The gain of the
chromosomal region 20q13.33-qter was observed in 37% of
both ODFs and corresponding OPMLs. Additional com-
mon regions included 7p22.2-pter, 11p15.5-pter and
16p13.3-pter where gains were observed. Furthermore,
gains of 20q13.31–q13.33 and of 5p13.33-pter and loss of
9p21.3 were detected at high frequency (respectively, at
62.5%, 50% and 50%) only in d-OPMLs. In particular, loss
at 9p21.3, gain at 5p13.33-pter and gain of 20q13.31–
q13.33 were associated with DNA aneuploidy (p=0.00004;
p=0.0005; p=0.01).
Conclusions ODFs and OPMLs showed common CNAs in
specific chromosomal regions suggesting that they may
represent early events of the natural history of oral
carcinogenesis according to the field effect cancerization
and may contribute to the ODF-OPML transition. In
addition, loss at 9p21.3 and gains at 5p13.33-pter and
20q13.31–q13.33 may contribute to DNA aneuploidization.
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1 Introduction
Accumulation of genetic/genomic aberrations are thought
to lead to a multi-step process of cancer genesis-
progression, in which the functions of genes controlling
the cell cycle, cell death, chromosomal stability, angiogen-
esis, invasion and metastasis become aberrant [1–3].
Epidemiologic and experimental evidences indicate that
most oral cancers originate and progress with the contribu-
tion of carcinogen exposure, mainly from tobacco smoking
[4, 5]. Recently, using parallel sequencing technology and a
lung cell line, a total of 22.910 somatic substitutions were
identified, including 134 in coding exons [6]. More than 60
chemicals derived from tobacco smoking that bind and
mutate DNAwithin the oral mucosa cells may contribute, in
particular, to create an extensive “field cancerization” [7–
9]. Specific gene mutations are also thought to contribute to
inhibit DNA repair and to increase DNA damage within the
entire mucosa and, in particular, to generate chromosomal
instability and aneuploidy resulting in an increased risk of
developing oral cancer. The theory of “field cancerization”
[7] and its more recent genetic explanation [8, 9] have
generated a very attractive genetic progression model of
oral cancer [10]. A critical step in this model, however, is
the conversion of a patch, in which stem cells share genetic/
genomic aberrations, into an expanding field with numer-
ous aberrations, which sometimes becomes visible as
leukoplakias [11–15]. Along the concepts of this model,
many studies have compared several types of DNA
aberrations within samples from oral cancer (mainly, oral
squamous cell carcinomas, OSCCs) and of oral tissue in the
vicinity of OSCCs. These studies include investigations on
loss of heterozygosity [9, 16, 17] and detection of
molecular and cellular aberrations by in situ hybridization
[18, 19], immunohistochemistry [18, 19], multiplex
ligation-dependent probe amplification [17], DNA image
[17] and flow cytometry [20].
Oral cancer was also characterized by different chromo-
somal aberrations located in specific chromosomal loci
including 1p36.3, 3q26, 7p, 8q, 9p, 11q13, 16p, 16q, 17q,
20q [21–27]. Recently, we have investigated the presence
of DNA aneuploid sublines by hr DNA-FCM within ODFs,
OPMLs and OSCCs, suggesting a model of DNA aneu-
ploidization [20, 28]. In the present study, we aimed to
investigate visually normal appearing and histologically
non-dysplatic mucosa fields (ODFs) distant with respect to
non-dysplastic and dysplastic OPMLs (nd- and d-OPMLs).
Our experimental approach was based on hr DNA-FCM
to detect DNA aneuploid sublines. DNA near-diploid
aneuploid sublines with a DI difference between 2 and
4% with respect to DNA diploid control cells could be
detected [20]. A DNA-FCM-Sorter was then used to
physically separate the epithelial DNA aneuploid sublines
in order to extract specific DNA to submit to a genome-
wide a-CGH analysis providing DNA copy number aberra-
tions (CNAs). These combined techniques may potentially
provide new evidence for the conversion of a patch
(represented by the ODFs) into an expanding field, which
became visible as leukoplakias (nd-OPMLs and d-OPMLs).
The first aim was to address whether the ODFs and the
OPMLs shared specific chromosomal changes. The second
aim was to compare chromosomal aberrations with DNA
aneuploidy to eventually identify genomic regions under-
lying the development of DNA aneuploid sublines.
2 Materials and methods
2.1 Patients and histological assessment
Patients with OPMLs were recruited in two different
medical centers: the Oral Medicine and Oral Oncology
Section of the University of Turin at the A.O.U. S. Luigi
Gonzaga (Orbassano-Turin) and at the Department of
Otolaryngology, “S. Martino Hospital” in Genoa. Patient
written consent was obtained in every case according to the
Institutional Ethic Committees (A.S.O. S. Luigi Gonzaga
Prot. N. 11780 and S. Martino Hospital Prot. N. 1084)
during an interview in which their tobacco and alcohol
habits were recorded.
Nineteen patients (9 males and 10 females, with a mean
age of 57.9 years, range 32–76 years) with nd- and d-
OPMLs, gave their informed consent and were included in
this study. The patients were also interviewed as to their
tobacco habit and the results were recorded: 8 patients were
non-smokers (NS) and 11 were smokers (S). Tissue samples
were obtained from both the OPMLs and from distal
corresponding ODFs in 18 out of 19 patients. The only
exception was the ODF of the patient 16, which allowed the
sampling of healthy tissue only from the buccal mucosa and
not from the tongue, which was the subsite affected by the
OPML. Sampling was performed by means of incisional
biopsy and/or micro-biopsy as previously detailed [29],
taking care to cause slight bleeding to ensure that the basal
layers of the epithelium had been collected. Part of the
sample was formalin-fixed to assess the presence of
dysplasia by means of routine haematoxylin and eosin
stained slides. Additional multiple samples were immedi-
ately frozen and stored at −20°C for later measurements by
hr DNA-FCM and a-CGH. The diagnosis of OPMLs (all
44 W. Giaretti et al.leukoplakias) was based on internationally accepted criteria
with levels of diagnostic certainty C3-C4 [30], while the
histological diagnosis for the assessment of the presence of
dysplasia was carried out by a specially trained pathologist,
according to the WHO guidelines [31]. The anatomical
subsites, which were in common in 18 out of 19 cases for
both ODFs/OPMLs, were for the vast majority of the cases
buccal mucosa. ODFs were not always equally distant from
the corresponding OPML lesions. In some cases, as for
example, when the OPMLs were on a cheek, the ODF
samples were obtained from the opposite cheek. This was
an optimal situation, which identifies the ODF position as
“controlateral” or “mirror” with respect to the OPML
position. On the contrary, when the lesion was on the
anterior floor of the mouth, ODFs could be too close to the
lesion. Therefore, OPMLs close to the midline were not
included in the present study. The anatomical subsites of
the ODFs/OPMLs are reported in Table 1.
2.2 Flow cytometric analysis and sorting
Multiple tissue samples were processed to obtain DAPI
stained nuclei suspensions following the method of Otto et
al. [32] with modifications. Hr DNA-FCM of these samples
was done as previously described in details using a
CyflowML cytometer (Partec GmbH, Muenster, Germany)
to obtain DNA content histograms and to evaluate the DNA
Index (DI) [33]. DNA diploid controls were represented by
gender-specific human lymphocytes. The mean CV of the
corresponding DNA diploid G0-G1 peaks was 1.2±0.2%.
DNA near-diploid aneuploid sublines with a DI difference
between 2 and 4% with respect to DNA diploid control
cells could be detected [20].The DNA aneuploid sublines
(DI≠1) were sorted using a Cyflow Space FCM equipped
with a PPCS unit (Partec GmbH) at the purity of about
99%.
2.3 DNA extraction
DNA extraction was performed using ArchivePure DNA
kit (5-Prime, Hamburg, Germany) with some modifications:
after proteins precipitation the DNA was purified by
phenol-chloroform extraction and collected by ethanol
precipitation using 20 μg of glycogen (20 mg/ml) as
carrier. DNA quality was assessed by agarose gel and
ND-1000 Spectrophotometer (NanoDrop Technologies,
Wilmington, DE).
2.4 Analysis by a-CGH
The a-CGH analysis was carried out using oligonucle-
otide Human Genome CGH 105 K array platform
(Agilent Technologies, Santa Clara, CA). A pool of
normal male or female DNA (Promega, Madison, WI)
was used as reference DNA. Briefly, 50 ng of genomic
DNA were amplified by GenomePlex Whole Genome
Amplification Kit WGA2 (Sigma-Aldrich, St. Louis,
MO). When the total amount of DNA was lower than
50 ng the amplification was performed by Ovation
WGA System (NuGEN, San Carlos, CA, USA). For
each array, amplified test and reference DNAs (2 μg
each) were labeled by Bioprime Labelling Kit (Invitro-
gen, Paisley, UK). Slides were hybridized and washed
according to manufacture’s recommendations. Spot
fluorescence was measured by the Agilent G2565BA
Scanner and images were processed by Feature Extrac-
tion software (version 9.5.3.1) (Agilent Technologies).
Data files were analyzed by Agilent CGH Analytics
Software (version 3.5.14) according to ADM-2 algo-
rithm. The quality of each experiment was assessed by
QC metric tool. Oligonucleotides were mapped accord-
ing to the human genome build NCBI35/Hg17 (May
2004). Raw data were uploaded in Gene Expression
Omnibus: (http://www.ncbi.nlm.nih.gov/projects/geo/
index.cgi, accession number: GSE28906). We have used
commercially available pooled normal DNA from healthy
donors. We excluded those copy number variations
(CNVs) that were listed as large segment copy number
polymorphisms by Genomic Variants Database (http://
projects.tcag.ca/variation).
Several tests were also performed to exclude that a-CGH
results could be affected by WGA, DAPI staining and the
DNA-FCM-Sorting (data not shown).
2.5 Statistical analysis
Data collection, management and analyses were done using
Microsoft Office Excel and the SPSS 16.0 software
package (Apache Software Foundation, Chicago, IL). The
association among variables in contingency tables was
evaluated with the Fisher exact test (two-sided) or the chi-
squared test. A p-value≤0.05 was taken as statistically
significant.
3 Results
Table 1 shows the main characteristics of the patients
(gender, age and tobacco smoking habit), the subsites, the
histology of the ODFs and OPMLs and the corresponding
DI values by DNA-FCM and CNAs by a-CGH. On the
basis of the histological diagnosis, the group of OPMLs in
the present series included 11 leukoplakias without dyspla-
sia (nd-OPMLs) and 8 dysplastic leukoplakias (d-OPMLs).
Dysplasia was never detected in the corresponding 19
ODFs. The frequencies of DNA aneuploidy in ODFs and
Genomic Aberrations in Normal Appearing Mucosa Fields 45Table 1 Patient’s and sample characteristics with DI values by hr DNA-FCM and CNAs by a-CGH for 19 ODFs and 19 OPMLs
Pt Gender Age Smoke
habit
Site Sample DI CNAs-Gains CNAs-Losses
1 F 56 S BM (c) ODF 1 None None
BM (c) nd-OPML 1 None None
2 F 39 S BM (c) ODF 1 None None
BM (c) nd-OPML 1 None None
3 F 55 S BM (c) ODF 1 None None
BM (c) nd-OPML 1 None None
4 M 70 NS BM (c) ODF 1 None None
BM (c) nd-OPML 1 2p12 None
5 F 68 S BM (c) ODF 1 11p15.5-pter; 16p13.3-pter;
20q13.33-qter
None
BM (c) nd-OPML 1 None None
6 M 58 NS BM (c) ODF 1 None None
BM (c) nd-OPML 1 None 5p15.33-pter; 7p22.3-pter;
8q24.3-qter; 10q26.3-qter;
11p15.5-pter; 12q24.33-qter;
16p13.3-pter; 20q13.3-qter;
21q22.3-qter
7 F 40 NS BM (c) ODF 1 None None
BM (c) nd-OPML 1 None None
8 F 50 S Others (hp) ODF 1 7p22.2-pter; 8q24.3-qter;
10q26.3-qter; 20q13.33-qter
None
Others (hp) nd-OPML 1 7p22.2-pter; 8q24.3-qter;
10q26.3-qter; 11p15.4-pter;
17q25.1-qter; 20q13.33-qter
None
9 M 41 S BM (rt) ODF 1.30 1p36.32-pter; 16p13.3-pter;
16q24.2-qter; 17q25.2-qter;
20q13.33-qter
None
BM (rt) nd-OPML 1 None None
10 M 32 NS BM (c) ODF 1 None None
BM (c) nd-OPML 1 None None
11 F 70 NS Tongue ODF 1 None None
Tongue nd-OPML 1.14 7p22.2-pter; 8; 12;
16p13.3-pter; 16q24.1-qter;
20q13.31-qter; X
9p21.3
12 M 63 S BM (c) ODF 1 None None
BM (c) d-OPML 1 None None
13 F 67 NS BM (c) ODF 1 1p36.32-pter; 7p22.2-pter;
8q24.3-qter; 9q33.3-qter;
10q26.3-qter; 11p15.4-pter;
16p13.3-pter; 16q23.3-qter;
17q25.1-qter; 20q13.33-qter;
21q22.3-qter; 22q13.33-qter
None
BM (c) d-OPML 1 1p36.32-pter; 4p16.2-pter;
7p22.2-pter; 8q24.3-qter;
9q33.3-qter; 10p26.3-pter;
11p15.4-pter; 14q32.2-qter;
16p13.3-pter; 16q23.3-qter;
20q13.31-qter; 21q22.3-qter
None
14 M 60 S BM (c) ODF 1 7p22.2-pter; 8q24.3-qter;
10p26.3-pter; 11p15.4-pter;
16p13.3-pter; 20q13.31-qter;
22q13.33-qter
None
BM (co) d-OPML 1 1p36.32-pter; 4p16.1-pter;
7p22.2-pter; 8q24.3-qter;
9q33.3-qter; 10q26.3-qter;
11p15.4-pter; 14q32.2-qter;
None
46 W. Giaretti et al.OPMLs were 5.3% and 32% respectively. The DI aneuploid
values among the ODFs and the nd-OPMLs were in all
cases near-diploid (DI≠1 and DI≤1.4), while in the d-
OPMLs were high-aneuploid (DI>1.4) in 40% of the cases
(Table 1).
Copy number aberrations (CNAs) were observed in 11/
19 OPMLs (58%) and in 7/19 ODFs (37%; Table 2). In 12
out of 19 ODFs (63%) and in 8/19 OPMLs (42%) no
aberrations were found. In particular, 6 ODFs (31.6%) and
the corresponding lesions showed a flat profile. ODFs and
the corresponding OPMLs had specific CNAs in common
in 5 out of 19 cases (29%). Two ODFs out of 19 (11%) had,
instead, unique CNAs that were absent in the corresponding
nd-OPMLs (Table1). The frequency of DNA aneuploidy,
which increased from 5.3% for the ODFs to 32% for the
OPMLs, was paralleled by an increase in the average
number of CNAs from 1.9 to 6.47 (Table 2). Moreover, the
presence of dysplasia among the OPMLs was associated
with an increased average number of CNAs (data not
shown).
It is of note that the CNA-gains were more frequent than
the CNA-losses among both the ODFs and the OPMLs. In
particular, the frequency of CNA-losses among the OPMLs
was 32% versus 0% among the ODFs (p=0.02, Fisher
exact test; Table 3). It is also of note that the presence of
DNA aneuploidy among all samples was concomitant with
an higher number of CNAs, both gains and losses. We also
observed that, while segmental chromosomal aberrations
(defined as CNAs within a chromosomal segment) were
present in both the DNA diploid and aneuploid sublines,
numerical chromosomal aberrations (gain/loss of entire
chromosomes) were seen only in presence of DNA
aneuploidy (Table 1).
Table 4 reports the CNA-gains of 6 minimal common
regions with the corresponding segment sizes and number
of genes. The most frequent aberrant common region was
Table 1 (continued)
Pt Gender Age Smoke
habit
Site Sample DI CNAs-Gains CNAs-Losses
16p13.3-pter; 16q24.1-qter;
17q25.1-qter; 19p13.1-pter;
20q13.31-qter; 21q22.3-qter;
22q13.32-qter
15 F 76 NS Others (g) ODF 1 None None
Others (g) d-OPML 1.04 2 None
16 M 59 S BM (c) ODF 1 None None
Tongue d-OPML 1.04 5p; 22q11.21; Yp 1p12-p21.1; 9p13.3-pter;
11q22.3-qter; 12p;
14q11-q31.3; Yq
17 M 62 S Others (sp) ODF 1 None None
Others (sp) d-OPML 1.20 1q; 2; 5; 8; 9p21.3-pter; 20 1p36.33-pter; 7p22.3-pter;
9p21.3; 10q26.3-qter;
11p15.5-pter;14q32.33-qter;
16p13.3-pter; 16q24.3-qter;
17q25.1-qter; 19p13,3-pter;
21q22.3-qter
18 M 64 S Tongue ODF 1 20q13.33-qter None
Tongue d-OPML 1.67 1q; 2p; 3q13.31-qter; 5p; 6;
7p; 8q; 10q; 11p15.5-pter;
11q13.2-q14.1; 12p;
13q12.12; 15; 16; 20;
22; Xp
2q11-q22.1; 3p12.1-p14.2;
3q12.1-q13.11; 4q13.1-q14.1;
5q11-q23.1; 7q21.11-q21.2;
8p12-pter; 9p21.3-pter;
9p11-p13.2; 9q; 10p11.21;
18q21.31-qter; Xq
19 F 71 NS Tongue ODF 1 1p36.32-pter; 7p22.2-pter;
11p15.5-pter; 20q13.33-qter;
21q22.3-qter
None
Tongue d-OPML 1.97 1p36.32-pter; 3q13.11-qter;
5p13.33-pter; 7p22.2-pter;
8q24.3-qter; 20q13.31-qter
6; 9p21.3; 13
Pt patient; DI DNA Index; CNA Copy number aberrations; NS non smoker; S: smoker; OFs: oral fields of visually normal mucosa; nd-OPMLs
non-dysplastic oral potentially malignant lesions; d-OPMLs dysplastic oral potentially malignant lesions; BM Buccal mucosa; c: cheek; hp hard
palate; rt retromolar trigone; co commissure; g gingiva; sp soft palate
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both the ODFs and the OPMLs. This aberrant region was
more commonly detected in the d-OPMLs (62.5%) than in
the nd-OPMLs (18%) (Table1). It is also of note that the
frequency of 7p22.2-pter gain was slightly lower in the
ODFs (21%) that in the OPMLs (32%). Similarly, the gain
of 8q24.3-qter was 16% for the ODFs and 37% for the
OPMLs. A cluster of 3 aberrations, the CNA-gains of the
7p22.2-pter, 8q24.2-qter and 20q13.33-qter regions, was
noted simultaneously in 16% of the ODFs, in 18% of the
nd-OPMLs and in 50% of the d-OPMLs.
In the present series of 19 OPMLs, 8 were charac-
terized by the presence of dysplasia (d-OPMLs) and of
unique types of aberrations, which were absent or at
very low frequency in all the other samples. Table 5
reports these aberrations, their start-end positions, segment
sizes and the corresponding number of genes: CNA-gains
in 5p13.33-pter, 16q24.2-qter and 20q13.31–q13.33 and a
CNA-loss in 9p21.3. The corresponding frequencies
among d-OPMLs were respectively 50%, 37.5%, 62.5%
and 50%.
In the present series of 19 ODFs and 19 OPMLs, 10
different aberrant chromosomal regions have been detected.
Table 6 presents the 2×2 contingency table tests of
association between these aberrant chromosomal regions
(CNAs with 9 gains and 1 loss) and the DNA ploidy status
(31 DNA diploid and 7 aneuploid samples). The association
was statistically significant for the chromosomal regions
5p13.33-pter (p=0.0005), 20q13.31–q13.33 (p=0.01) and
9p21.3 (p=0.00004). It is of note that the 20q gain, which
extends beyond 20q13.33 up to 20qter and was commonly
present among the ODFs/OPMLs (14/38=37%) was only
slightly associated with DNA aneuploidy (p=0.077).
4 Discussion
The concept of field cancerization in oral cancer has been
widely described and discussed [7–10] suggesting that
premalignant changes may occur in any region of the oral
mucosa exposed to carcinogens. According to Dakubo
et al., the field cancerization represents a “process whereby
cells in a particular tissue or organ are transformed, such
that genetically altered but histologically normal appearing
cells predate the development of neoplasia or coexist with
malignant cells, irrespective of clonality” [34].
More than 60 chemicals derived from tobacco smoking
that may bind and mutate a large number of genes [6] may
contribute to create such an extensive oral field of cancer-
ization. Along these concepts, a very attractive genetic
progression model of oral cancer was proposed [10]. A
critical step in this model, however, appears the transition
from an early precursor to an expanding field with
numerous aberrations, which sometimes becomes visible
as leukoplakias or oral potentially malignant lesions
(OPMLs) [11–15].
In recent years, the powerful technique of Comparative
Genomic Hybridization (metaphase-CGH and, more lately,
array-CGH) has provided a genome-wide analysis of DNA
copy number aberrations (CNAs) suggesting that CNA
gains and losses may result respectively in hyper- and
hypo-expression of specific genes [35]. These studies,
which mainly analyzed oral squamous cell carcinomas
(OSCCs) and more rarely OPMLs, have identified several
aberrant chromosomal loci including 1p36.3, 3q26, 5p, 7p,
8q, 9p, 11q13, 16p, 16q, 17q, 20q and have contributed to a
better understanding of the development of oral cancer and
of its clinical implications [11–15, 21–27].
Table 2 DNA ploidy and CNAs among ODFs and OPMLs
DNA ploidy by hr DNA-FCM CNAs by a-CGH
DNA diploid
(DI=1)
DNA aneuploid
(DI≠1)
absent present range average
ODFs (n=19) 18 (94.7%) 1 (5.3%) 12 (63.2%) 7 (36.8%) 1–12 1.9
OPMLs (n=19) 13 (68.4%) 6 (31.6%) 8 (42.1%) 11 (57.9%) 1–30 6.47
Table 3 Relative number of
ODFs and OPMLs with CNA-
gains and CNA-losses
ODFs OPMLs Fisher exact test (p=)
CNA—gains
absent 12 (63.2%) 9 (47.4%) 0.5
present 7 (36.8%) 10 (52.6%)
CNA—losses
absent 19 (100%) 13 (68.4%) 0.019
present 0 (0%) 6 (31.6%)
48 W. Giaretti et al.In the present study, we demonstrated that the vast
majority of these aberrant chromosomal regions were
already present in our series of OPMLs and corresponding
non-dysplastic visually normal mucosa oral fields (ODFs).
In particular, some specific CNAs that were present at high
frequencies (between 40 and 60%) in the d-OPMLs (for
example, loss at 9p21.3 and gain at 20q13.31–q13.33) were
absent or at very low frequency in all the other samples.
The additional use of high resolution DNA flow
cytometry (hr DNA-FCM) carries two relevant advantages.
First, it allows (with the use of the technical capability of
DNA-FCM-Sorting) to identify the presence of DNA
aneuploid sublines and to physically separate them from
the DNA diploid components and to submit therefore a
relatively pure population of epithelial aneuploid nuclei to
a-CGH. Second, this combined approach made it possible
to compare the DNA aberrations obtained by hr DNA-FCM
and a-CGH and to eventually indicate genomic regions
underlying the development of DNA aneuploid sublines.
Among the 10 different aberrant chromosomal regions
that we have detected for both ODFs and OPMLs, we
found that loss at 9p21.3 and gains at 5p13.33-pter and
20q13.31–q13.33 were associated with DNA aneuploidy
(p=0.00004; p=0.0005; p=0.01). Though based on a
relatively small number of ODF/OPML samples (n=38),
these results represent a new finding, which suggests that
candidate genes within these chromosomal regions may be
linked with mechanisms of chromosomal instability and
aneuploidy. In particular, the chromosomal loss in the
region 9p21.3 appears to be an interesting one, because it is
characterized by a small size of only 2.16 Mb and only 9
genes, because 50% of the d-OPMLs lost this region and
also because it is strongly correlated with DNA aneuploidy.
Clearly, only specific types of studies may identify which
specific gene/s may be responsible for such an important
change as DNA aneuploidization. As far as known function
of genes located in this region, we recall the gene CDKN2A
(Cyclin-dependent kinase inhibitor 2A or TP16). This
tumor suppressor gene, which is frequently inactivated by
methylation, gene mutation and allelic deletions, was reported
toplayanimportant roleinthe carcinogenesisofOSCCs[36].
Also the chromosomal region 5p15.33-pter (segment size=
1.9), which was similarly associated with DNA aneuploidy,
is an interesting one. Within this region, we recall the hTERT
gene (Telomerase reverse transcriptase), which was impli-
cated in telomerase-mediated chromosomal instability along
with cell growth and apoptosis imbalances [37, 38].
Finally, we like to cite the RTEL1 gene (Regulator of
telomere elongation helicase 1) located in the 20q13.33-qter
region, which was commonly present among the ODFs/
OPMLs. This gene was reported to play a crucial role in
telomere maintenance, chromosomal instability, DNA repair,
negative regulation of apoptosis and was found to be
amplified in several human cancers [39–42].
Clearly, the identification of genes responsible for
chromosomal instability and aneuploidization in the early
phases of oral carcinogenesis represented by ODFs and
OPMLs would be a very important task. With respect to our
a-CGH data, we have also posed this question: have the
ODFs and the OPMLs some chromosomal aberrations in
common? The observation that some CNAs at specific
chromosomal regions for the ODFs (1p36.32-pter, 7p22.2-
Table 4 Detailed overview of minimal common region CNA-gains in ODFs and OPMLs
Common CNA-gains Position (bp) Segment size n° of genes ODFs (n=19) OPMLs (n=19)
Start End Mb
1p36.32-pter 604268 4312064 3.71 41 3 (16%) 3 (16%)
7p22.2-pter 149268 1973885 1.82 14 4 (21%) 6 (32%)
8q24.3-qter 142173802 146250824 4.08 69 3 (16%) 7 (37%)
11p15.5-pter 186966 2789993 2.60 53 4 (21%) 4 (21%)
16p13.3-pter 36766 2592859 2.56 84 4 (21%) 4 (21%)
20q13.33-qter 59483462 62194881 2.71 52 7 (37%) 7 (37%)
Table 5 Unique types of CNAs
present in the d-OPMLs that
were absent or at very low
frequency in all the other
samples
CNAs Position (bp) Segment size n° of genes d-OPMLs (n=8)
Start End Mb
Gains 5p15.33-pter 75149 2038701 1.9 21 4 (50.0%)
16q24.2-qter 85963377 88690615 2.73 49 3 (37.5%)
20q13.31-q13.33 55096989 59483462 4.39 30 5 (62.5%)
Loss 9p21.3 21114875 23278698 2.16 9 4 (50.0%)
Genomic Aberrations in Normal Appearing Mucosa Fields 49pter, 8q24.2-qter, 11p15.5-pter, 16p13.3-pter, 20q13.33-
qter) were also present (in almost all cases at increasing
frequencies) for the OPMLs might suggest that these
aberrations could have played a role in the ODF-OPML
transition and that they may be clonally related. In other
words, the ODFs might represent in some cases an early
precursor of the OPMLs of the same patient. It is to be
noticed, however, that two ODFs with CGH aberrations had
2 corresponding nd-OPMLs without aberrations. This
might also imply that the origin of either ODFs or nd-
OPMLs may be polyclonal. Clearly, we are well aware that
these chromosomal aberrant regions are quite large and
might contain a large number of genes beside those
eventually involved in the ODF-OPML transition.
With respect to the hr DNA-FCM data, we found that
among the 19 ODFs of the present series, only one was
characterized by a DNA Index value different from 1 (DI≠
1), i.e., by a DNA aneuploid subpopulation (1/19=5.26%).
On the contrary, DNA aneuploid subpopulations were
detected in 6 out of 19 OPMLs (32%). These results
suggest that DNA aneuploidization is a relatively frequent
early event in OPMLs and that sporadically such early
aberration may already occur in ODFs within the same
anatomical subsite. In no cases, however, we detected a
common DNA aneuploid subline (with the same DI value)
in both ODFs and corresponding OPMLs. Clearly, a much
greater number of cases is needed to address this question.
These data are in agreement with an independent study
performed only by DNA-FCM in which we found that the
percentage of DNA aneuploid ODFs and OPMLs were
respectively 8.5% and 28% [20].
The absence of a DNA aneuploid component in the pure
DNA diploid samples did not allow an enrichment of the
epithelial component and therefore diploid stromal cells were
alsopresentwiththeepithelialcells.Itisalsotobenoticedthat
the amount of material was not sufficient to obtain DNA
diploidsuspensionsofcellstobemarkedandsortedaccording
to epithelial specific antibodies and then to be reduced to
nuclei suspensions and extracted DNA. The presence of
epithelial cells (at least 50%) in the DNA diploid samples was
controlled by morphological inspection from tissue samples
obtained in parallel with the ODF/OPML samples.
In conclusion, specific aberrant chromosomal regions
detected by high resolution a-CGH in oral visually and
histologically normal fields and in potentially malignant
lesions appear to be early events of the natural history of
oral cancer associated with an early onset of the field
cancerization and with DNA aneuploidy. Work remains to
be done to identify possible specific genes within the CNA
common regions, which might potentially contribute to the
ODF-OPML transition and to DNA aneuploidization. The
detection of these genomic aberrations, including DNA
aneuploidy, which is prone to routine analysis, may help to
identify individual patients with OPMLs at high risk to
develop OSCCs and indicate alternative criteria for the
management of these patients [34, 43–45]. Clearly, the
validation of this hypothesis requires long term prospective
follow-up studies with an appropriate number of cases.
Table 6 Loss at 9p21.3, gain at
5p13.33-pter and gain of
20q13.31–q13.33 were
associated with DNA
aneuploidy
ODFs + OPMLs
CNAs DNA diploid (n=31) DNA aneuploid (n=7) p=(Fisher test)
Gains 1p36.32-pter absent 27 5 0.3
present 4 2
5p13.33-pter absent 31 3 0.00047
present 0 4
7p22.2-pter absent 24 4 0.35
present 7 3
8q24.3-qter absent 25 3 0.062
present 6 4
11p15.5-pter absent 24 6 1
present 7 1
16p13.3-pter absent 26 4 0.14
present 5 3
16q24.2-qter absent 28 4 0.063
present 3 3
20q13.31-q13.33 absent 28 3 0.013
present 3 4
20q13.33-qter absent 22 2 0.077
present 9 5
Loss 9p21.3 absent 31 2 0.000041
present 0 5
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